Novartis
News/ News/ News/ Oncology/ Sales and Marketing
Novartis bags FDA okay for BRAF-positive tumour combination
Phil Taylor
BRAF, Mekinist, Novartis, novel targeted cancer treatments, Oncology, Tabrecta, Tafinlar
0 Comment
Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis
Phil Taylor
beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease
0 Comment
News/ News/ Sales and Marketing
Novartis faces threat of early generic of MS drug Gilenya in US
Phil Taylor
generics, multiple sclerosis, Novartis, patent litigation
0 Comment
News/ News/ News/ Oncology/ R&D
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Phil Taylor
acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata
0 Comment
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Phil Taylor
Amgen, atherosclerosis, gene silencing, lipoprotein(a), Novartis, olpasiran, pelacarsen, Silence Therapeutics, siRNA, SLN360
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Roche puts pressure on SMA rivals with new FDA approval
Phil Taylor
Biogen, Evrysdi, Novartis, PTC Therapeutics, regulatory approval, Roche, SMA, Spinraza, Zolgensma
0 Comment
Patients/ Views & Analysis/ Views and analysis
A crisis of trust: How lack of sector confidence is threating patient centricity
Amanda Barrell
Novartis, patient centricity, Scott Bradley, trust in pharma
0 Comment